Edition:
United Kingdom

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

0.90USD
14 Jun 2019
Change (% chg)

$-0.00 (-0.01%)
Prev Close
$0.90
Open
$0.87
Day's High
$0.90
Day's Low
$0.87
Volume
545
Avg. Vol
184,945
52-wk High
$3.25
52-wk Low
$0.61

Latest Key Developments (Source: Significant Developments)

Dare Bioscience Files For $1.6 Mln Common Stock Offering - SEC Filing
Friday, 31 May 2019 

May 31 (Reuters) - Dare Bioscience Inc ::DARE BIOSCIENCE INC - FILES FOR $1.6 MILLION COMMON STOCK OFFERING - SEC FILING.  Full Article

Daré Bioscience Reports Qtrly Loss Per Share $0.27
Tuesday, 14 May 2019 

May 14 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND COMPANY UPDATE.DARE BIOSCIENCE INC - QTRLY LOSS PER SHARE $0.27.DARE BIOSCIENCE INC - AS OF MARCH 31, 2019, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $3.5 MILLION.  Full Article

Daré Bioscience Prices Underwritten Public Offering Of Common Stock
Tuesday, 9 Apr 2019 

April 9 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. PRICES UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.58 MILLION COMMON SHARES PRICED AT $1.10PER SHARE.  Full Article

Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil
Monday, 2 Apr 2018 

April 2 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.DARE BIOSCIENCE - INTENDS TO COMMUNICATE WITH U.S. FDA IN MID-2018 REGARDING PHASE 2B STUDY OF TOPICAL SILDENAFIL.ANTICIPATES COMMENCING A PHASE 2B STUDY OF TOPICAL SILDENAFIL IN Q4 OF 2018.  Full Article

CVI Investments Reports 8.8 Pct Passive Stake In Dare Bioscience As Of Feb 13
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - CVI Investments :CVI INVESTMENTS REPORTS AN 8.8 PERCENT PASSIVE STAKE IN DARÉ BIOSCIENCE AS OF FEB 13- SEC FILING.  Full Article

Dare Bioscience Inc To Raise About $10.25 Mln
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. TO RAISE APPROXIMATELY $10.25 MILLION.DARE BIOSCIENCE -EACH SHARE BEING SOLD TOGETHER WITH WARRANT TO BUY UP TO .70 OF A SHARE OF COMMON STOCK, AT EXERCISE PRICE OF $3.00/SHARE.  Full Article

Daré Bioscience Announces Proposed Public Offering Of Common Stock
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DARE BIOSCIENCE - INTENDS TO OFFER PRIMARY SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK IN A PUBLIC OFFERING.  Full Article

Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER.DARE BIOSCIENCE INC - ‍ENTERED INTO AN AGREEMENT TO LICENSE SST-6007​.DARE BIOSCIENCE INC - ‍DARÉ ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL IN SECOND HALF OF 2018 FOR SST-6007​.  Full Article

Dare Bioscience Says Entered Into Common Stock Sales Agreement
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Dare Bioscience Inc ::DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING.DARE BIOSCIENCE - UNDER AGREEMENT, CO MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $10 MILLION.  Full Article

Daré Bioscience announces MoU with CONRAD for conduct of Ovaprene postcoital test clinical trial
Monday, 24 Jul 2017 

July 24 (Reuters) - Dare Bioscience Inc ::Daré Bioscience, Inc announces memorandum of understanding with Conrad for the conduct of the Ovaprene® postcoital test clinical trial.Final details will be negotiated under a separate agreement.  Full Article